Safety and activity of Diakine DK210 (EGFR), a next generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial.
Wednesday, June 19, 2024
Dr. Douglas Orr
Click the above link to view the abstract.
![ASCO 2024 Poster for Trial 23-08](https://marycrowley.org/wp-content/uploads/2024/06/Poster-13.jpg)
ASCO 2024 Poster for Trial 23-08